利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.028 秒)

    Methods for imaging the lymphatic system using dendrimer-based contrast agents
    1.
    发明申请
    Methods for imaging the lymphatic system using dendrimer-based contrast agents 审中-公开
    使用基于树枝状大分子的造影剂对淋巴系统成像的方法

    公开(公告)号：US20050171424A1

    公开(公告)日：2005-08-04

    申请号：US10756948

    申请日：2004-01-13

    申请人： Martin Brechbiel ,  Hisataka Kobayashi ,  Peter Choyke ,  John Morris ,  Thomas Waldmann

    发明人： Martin Brechbiel ,  Hisataka Kobayashi ,  Peter Choyke ,  John Morris ,  Thomas Waldmann

    IPC分类号： A61K49/00 ,  A61K49/08 ,  A61K49/12 ,  A61K49/18 ,  A61B5/05 ,  A61B5/055

    CPC分类号： A61K49/124 ,  A61K49/0002 ,  A61K49/189 ,  B82Y5/00

    摘要： Methods are disclosed for lymphatic system imaging using dendrimer conjugates as contrast agents. The disclosed methods are applicable to the imaging of all lymphatic structures, but in particular embodiments are particularly suited for imaging specific parts of the lymphatic system such as lymph nodes or lymphatic vessels. The methods permit the assessment of abnormal conditions within the lymphatic system, such as lymphoma/lymphoproliferative disease, inflammation, and cancer metastasis. The methods also may be used to identify and locate lymph nodes into which lymph fluid flows from a tumor.

    摘要翻译： 公开了使用树枝状大分子缀合物作为造影剂的淋巴系统成像的方法。 所公开的方法适用于所有淋巴结构的成像，但是在具体实施方案中特别适合于成像诸如淋巴结或淋巴管的淋巴系统的特定部分。 该方法允许评估淋巴系统内的异常状况，例如淋巴瘤/淋巴增生性疾病，炎症和癌症转移。 这些方法还可用于鉴定和定位淋巴结从淋巴液流向其中的淋巴结。

    METHODS OF PREVENTING OR TREATING T CELL MALIGNANCIES BY ADMINISTERING ANTI-CD2 ANTAGONISTS
    9.
    发明申请
    METHODS OF PREVENTING OR TREATING T CELL MALIGNANCIES BY ADMINISTERING ANTI-CD2 ANTAGONISTS 审中-公开
    通过管理抗CD2拮抗剂预防或治疗T细胞恶性肿瘤的方法

    公开(公告)号：US20110280868A1

    公开(公告)日：2011-11-17

    申请号：US12466852

    申请日：2009-05-15

    申请人： Christine Dingivan ,  Thomas Waldmann ,  Zhuo Zhang ,  Meili Zhang

    发明人： Christine Dingivan ,  Thomas Waldmann ,  Zhuo Zhang ,  Meili Zhang

    IPC分类号： A61K39/44 ,  A61P35/00 ,  A61P35/02 ,  A61K39/395

    CPC分类号： C07K16/2806 ,  A61K2039/505 ,  C07K2317/24

    摘要： The present invention encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof as a single agent therapy for the prevention, treatment, management, or amelioration of cancer, particularly a T-cell malignancy, or one or more symptoms thereof. The present invention also encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in amounts effective to prevent, treat, manage, or ameliorate cancer, particularly a T-cell malignancy, or one or more symptoms thereof.

    摘要翻译： 本发明包括CD2拮抗剂，优选MEDI-507，其类似物，衍生物或抗原结合片段作为单一药物治疗用于预防，治疗，治疗或改善癌症，特别是T细胞的用途 恶性肿瘤，或其一种或多种症状。 本发明还包括CD2拮抗剂，优选MEDI-507，其类似物，衍生物或其抗原结合片段与其它癌症疗法的组合的用途。 本发明提供药物组合物，其包含有效预防，治疗，治疗或改善癌症，特别是T细胞恶性肿瘤的CD2拮抗剂，优选MEDI-507，其类似物，衍生物或抗原结合片段，或一种 或更多的症状。